|
"whangpeng j"的相關文件
顯示項目 1-9 / 9 (共1頁)
1
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
1997-10 |
Cross regulation by IL-10 and 1L-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients
|
Chen, YM; Yang, WK; Ting, CC; Tsai, WY; Yang, DM; WhangPeng, J; Perng, RP |
| 國家衛生研究院 |
1997-09 |
Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients
|
Chen, YM; Yang, WK; WhangPeng, J; Tsai, WY; Hung, YM; Yang, DM; Lin, WC; Perng, RP; Ting, CC |
| 國家衛生研究院 |
1997-07-15 |
Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis
|
Huang, TS; Shu, CH; Yang, WK; WhangPeng, J |
| 國家衛生研究院 |
1997-07 |
A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions
|
Perng, RP;Wu, MF;Lin, SY;Chen, YM;Lin, JY;WhangPeng, J |
| 國家衛生研究院 |
1997-05 |
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study
|
Perng, RP; Chen, YM; MingLiu, J; Tsai, CM; Lin, WC; Yang, KY; WhangPeng, J |
| 國家衛生研究院 |
1997-04 |
Mitomycin-C induced hemolytic uremic syndrome: A case report and literature review
|
Wu, DC;Liu, JM;Chen, YM;Yang, SL;Liu, SM;Chen, LT;WhangPeng, J |
| 國家衛生研究院 |
1997-04 |
Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer
|
Chen, YM;Wu, MF;Perng, RP;Chou, CM;Yang, KY;Lin, WC;Tsai, CM;Liu, JM;WhangPeng, J |
| 國家衛生研究院 |
1996-12-20 |
Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide
|
Huang, TS; Shu, CH; Shih, YL; Huang, HC; Su, YC; Chao, Y; Yang, WK; WhangPeng, J |
| 國家衛生研究院 |
1996-07-17 |
Paclitaxel-induced severe neuropathy in patients with previous radiotherapy to the head and neck region
|
Liu, JM; Chen, YM; Chao, Y; Liu, TW; Chou, CM; Chen, LT; Yu, WL; WhangPeng, J |
顯示項目 1-9 / 9 (共1頁)
1
每頁顯示[10|25|50]項目
|
